Use of mobile and sensor technology lowers symptom severity for people with head and neck cancer

May 17, 2018 by Kelly Baldwin, American Society of Clinical Oncology
Use of mobile and sensor technology lowers symptom severity for people with head and neck cancer
Credit: American Society of Clinical Oncology

A federally funded, randomized clinical trial of 357 people receiving radiation for head and neck cancer, using mobile and sensor technology to remotely monitor patient symptoms, resulted in less severe symptoms related to both the cancer and its treatment (both general and cancer-related).

Patients who used the technology—which included a Bluetooth-enabled weight scale, Bluetooth-enabled blood pressure cuff, and mobile tablet with a symptom-tracking app that sent information directly to their physician each weekday—had lower symptom severity than participants who had standard weekly visits with their doctors.

In addition, daily remote tracking of patient wellbeing, according to the researchers, enabled physicians to detect concerning symptoms early and respond more rapidly, compared to usual care. These findings will be presented at the upcoming 2018 ASCO Annual Meeting in Chicago.

"Our study generated evidence on how newer technologies can be integrated into cancer care relatively easily and improve patient outcomes without interfering too much in a person's daily life," said lead study author Susan K. Peterson, Ph.D., professor, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston. "This study was done during a rather intense period in the patients' care for head and . The system helped their physicians to provide valuable support that ultimately resulted in lower symptom severity."

About Head and Neck Cancer

An estimated 51,540 new head and neck cancers will be diagnosed in the United States in 2018.1 Just over 10,000 people are expected to die of the disease, with men accounting for three-quarters of these deaths.

Most people diagnosed with this form of cancer receive radiation therapy but can also have chemotherapy or surgery. One of the major side effects of treatment that requires careful monitoring is pain and difficulty swallowing, which can lead to dehydration.

About the Study

This trial used a technology system called CYCORE (CYberinfrastructure for COmparative Effectiveness REsearch), developed collaboratively by four institutions through a grant from the National Cancer Institute.

Participants were randomly assigned to CYCORE (169 people) or usual care (188 people), which consisted of weekly doctor visits. People in the CYCORE group received sensors (blood pressure cuffs and weight scales) that were Bluetooth-enabled. They also got mobile tablets with proprietary Wi-Fi. An in-home wide area network (WAN) hub/router transmitted their sensor readouts, and a mobile app transmitted their symptom data through a back-end cyber-infrastructure to secure firewall-protected computers at MD Anderson to ensure patient information confidentiality.

For the CYCORE group, physicians reviewed data from the app and sensor transmissions remotely each weekday and could intervene in a person's care if necessary. Both CYCORE and usual care participants had weekly in-person doctor visits.

At the start of radiation therapy, study participants completed a 28-item MD Anderson Symptom Inventory survey about their health and common activities of daily living. The survey covered general symptoms that are common in people with cancer, such as pain, fatigue, and nausea, as well as symptoms that are particularly relevant to people with head and neck cancer, such as difficulty swallowing or chewing, skin pain/burning/rash, and problems with tasting food. The participants completed a similar survey at the end of their radiation therapy, usually 6 to 7 weeks later. A final survey was completed 6 to 8 weeks after their radiation therapy ended.

Key Findings

There was no difference in self-reported health severity scores between the CYCORE participants and those who received usual care at the start of the trial. Symptoms severity was scored on a scale of 0 to 10, with zero being no symptom or pain and 10 being the highest level of severity. After completion of , the CYCORE participants had lower (i.e. better) mean scores for general symptoms vs. usual care participants (2.9 vs. 3.4), as well as lower mean scores for symptoms specific to head and neck cancer (4.2 vs. 4.8).

Six to 8 weeks after completion of therapy, CYCORE participants had a mean score of 1.6 vs. 1.9 for usual care participants based on overall health. Both groups had slightly higher severity scores for specific head and neck symptoms (1.7 vs. 2.1).

Most patients (80% or more) adhered to daily monitoring, which was an excellent outcome given the intensity of their treatments, noted Dr. Peterson. Scores reflecting how various symptoms interfered in activities of daily living were about the same in both groups across the entire time of survey reporting.

Limitations and Next Steps

While the authors were able to recruit people from a wide range of ages, the study population was mostly white, which closely reflected the overall head and neck patient population at the cancer center. The next step for researchers may be to determine how long the benefit of a CYCORE intervention could persist. They also hope to implement the CYCORE intervention in non-academic cancer treatment settings where the majority of patients receive their treatment.

Explore further: Acupuncture and cognitive behavioral therapy for treating insomnia in cancer survivors

More information: abstracts.asco.org/214/AbstView_214_230683.html

Related Stories

Acupuncture and cognitive behavioral therapy for treating insomnia in cancer survivors

May 17, 2018
A Patient-Centered Outcomes Research Institute (PCORI)-supported randomized clinical trial of cancer survivors showed that eight weeks of either acupuncture or cognitive behavioral therapy for insomnia (CBT-I) decreased the ...

Electronic patient-reported symptom monitoring associated with increased survival among patients

June 4, 2017
The integration of electronic patient-reported outcomes into the routine care of patients with metastatic cancer was associated with increased survival compared with usual care, according to a study published by JAMA. The ...

Nivolumab immunotherapy safe, feasible during chemoradiation for adv. head and neck cancer

February 13, 2018
Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced ...

Symptom burden may increase hospital length of stay, readmission risk in advanced cancer

October 23, 2017
Hospitalized patients with advanced cancer who report more intense and numerous physical and psychological symptoms appear to be at risk for longer hospital stays and unplanned hospital readmissions. The report from a Massachusetts ...

Depressive symptoms linked to shorter survival in patients with head and neck cancer

January 22, 2018
In a study of patients with head and neck cancer, even mild depressive symptoms were associated with poorer overall survival. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings ...

Smartphone app monitors cancer patients recovery

December 20, 2017
Cancer patients receiving chemotherapy can be remotely monitored using their smartphone sensors and an algorithm that detects worsening symptoms based on objective changes in patient behavior, according to a new study from ...

Recommended for you

Chemicals found in vegetables prevent colon cancer in mice

August 14, 2018
Chemicals produced by vegetables such as kale, cabbage and broccoli could help to maintain a healthy gut and prevent colon cancer, a new study from the Francis Crick Institute shows.

Researchers artificially generate immune cells integral to creating cancer vaccines

August 14, 2018
For the first time, Mount Sinai researchers have identified a way to make large numbers of immune cells that can help prevent cancer reoccurrence, according to a study published in August in Cell Reports.

Lymphatic vessels unexpectedly promote the spread of cancer metastases

August 14, 2018
Lymphatic vessels actively contribute to the spread of cancer metastases from various organs. This unexpected realisation is the result of a joint study by researchers from ETH Zurich and the University Hospital Zurich as ...

Ovarian cancer genetics unravelled

August 14, 2018
Patterns of genetic mutation in ovarian cancer are helping make sense of the disease, and could be used to personalise treatment in future.

Researchers uncover a major new vulnerability of childhood leukemia

August 14, 2018
Childhood leukemia is a diagnosis that no family ever wants to endure. While the treatment of most types of leukemia has improved steadily over the years, a few specific types remain very difficult to treat. One of these ...

Stress hormone is key factor in failure of immune system to prevent leukemia

August 14, 2018
The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.